AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$MYGN

Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised

Myriad Genetics (MYGN) reported Q3 2026 revenue of $202.7M, down 1% YoY, with prenatal health testing volume down 11%. Hereditary cancer testing revenue per test fell 6% YoY. Adjusted EBITDA loss was $5.3M, and adjusted EPS loss was $0.11. The company raised full-year revenue guidance to $785M and plans to divest its prenatal health business, expecting improved growth and margins post-divestiture.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 9:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MYGNNeutralMed
01

Why it matters

The raised revenue guidance and cash proceeds from the divestiture provide a modest catalyst, but testing reimbursement pressures remain a risk.

02

Market read

Guidance raise and divestiture news could move MYGN modestly in pre‑market trading, while broader sector faces pricing headwinds.

03

What to watch

Potential impact of the prenatal business divestiture on cash flow and debt repayment could improve balance sheet flexibility.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Myriad Genetics reported Q3 2026 results, highlighted a modest revenue decline, ongoing EBITDA loss, and announced the sale of its prenatal health business to LabCorp for $210 million.

Company-level read

Ticker impact

$MYGNNeutralMedium confidence
Context

Q3 earnings call disclosed a 1% YoY revenue decline and raised full-year 2026 revenue guidance to $785 million.

Expected impact

potential modest upside as the market prices in the raised guidance

Evidence & confidence

The guidance increase signals slight improvement, but persistent EBITDA loss and testing headwinds keep risk elevated.

Market effects

Sector

Hereditary cancer testing sector may face pricing pressure, but Myriad's divestiture could sharpen focus on cancer care continuum.

Regional

U.S. biotech investors may react to the guidance raise and ongoing profitability challenges.

Global

Limited; primarily impacts U.S. specialty diagnostics market.

Counterpoint

What could challenge this read

The guidance raise may be insufficient given the company's loss profile and testing reimbursement headwinds.

Key entities

  • company
    Myriad Genetics Inc

    U.S. specialty diagnostics firm focusing on hereditary cancer and prenatal testing.

  • company
    LabCorp

    Acquirer of Myriad's prenatal health business.

Read at source← All news

StoryMyriad Genetics raises FY 2026 revenue outlook and announces prenatal business divestiture

Also covered by

3 outlets

Related articles

$MYGNMed

Myriad Genetics Q3 Earnings Call Highlights

Myriad Genetics (NASDAQ:MYGN) expects revenue growth and gross margin improvements post-divestiture. Q3 revenue rose 1% to $124M, with hereditary cancer test volume up 6%. The company raised 2026 revenue guidance to $780M-$790M. GeneSight test revenue increased 2% to $40M. Myriad plans to manage Precise MRD test demand until reimbursement begins in 2027 and is pursuing cost-cutting initiatives.

finance.yahoo.com
$MYGNHighAI 8/10

Myriad Genetics Reports Third Quarter 2026 Financial Results

MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights • Third quarter 2026

SEC EDGAR 8-K
$LHHighAI 9/10

Labcorp adds more diagnostic services

Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.

thetimesnews.com